基因重组γ干扰素在治疗变应性鼻炎中的作用

目的研究基因重组γ干扰素在治疗变应性鼻炎中的作用.方法采用随机对照研究方法将60例变应性鼻炎患者分成两组,每组30例,一组予常规脱敏治疗(对照组),另一组予常规脱敏治疗加基因重组γ干扰素治疗(实验组),6个月后比较两组的症状评分、血清白细胞介素-4(IL-4)、嗜酸粒细胞阳离子蛋白(ECP)水平.结果对照组治疗前、后症状评分分别为10.6±2.3和4.2±1.8,血清IL-4水平分别为(545.3±86.2)ng/L和(320.4±76.3)ng/L,ECP水平分别为(24.3±8.2)μg/L和(12.4±6.3)μg/L;实验组治疗前、后症状评分分别为10.8±2.7和3.5±1.6,血清IL-4水平分别为(547.8±84.6)ng/L和(280.4±87.3)ng/L,ECP水平分别为(25.1±7.7)μg/L和(10.4±5.1)μg/L.实验组治疗后症状评分、IL-4和ECP水平均低于对照组(均P<0.05).结论基因重组γ干扰素能改善变应性鼻炎症状,降低血清IL-4、ECP水平,在变应性鼻炎的治疗中发挥着免疫调节作用.

Survey of the therapeutic reactions of CLONGAMMA in allergic rhinitis

OBJECTIVE: To evaluate the efficacy of IFN-gamma for treatment of allergic rhinitis. METHOD: Sixty patients studied were divided into 2 groups randomly. The control group was given specific immunotherapy, the observe group was given specific immunotherapy and IFN-gamma treatment (1000000 IU im qod). Symptom score and level of serum IL-4 and ECP were compared pre and post treatment in two groups after 6 month. RESULT: In control group, the symptom score were 10.6 +/- 2.3 and 4.2 +/- 1.8 pre and post therapy, IL-4 were (545.3 +/- 86.2) ng/L and (320.4: +/- 76.3) ng/L, ECP were (24.3 +/- 8.2) microg/L and (12.4 +/- 6.3) microg/L. In observe group, the symptom score were 10.8 +/- 2.7 and 3.5 +/- 1.6 pre and post therapy, IL-4 were (547.8 +/- 84.6) ng/L and (280.4 +/- 87.3) ng/L, ECP were (25.1 +/- 7.7) microg/L and (10.4 +/- 5.1) microg/L. All the data P < 0.05. And after the therapy, there were significant difference in the observe group and the control group. CONCLUSION: IFN-gamma may modulate the immune system and was effective in the treatment for allergic rhinitis.